ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
68.41
+0.74 (+1.09%)
At close: 4:00PM EDT

68.41 0.00 (0.00%)
After hours: 6:50PM EDT

Stock chart is not supported by your current browser
Previous Close67.67
Open67.76
Bid65.80 x 1000
Ask0.00 x 3200
Day's Range67.76 - 68.57
52 Week Range51.37 - 68.82
Volume5,017,956
Avg. Volume4,694,987
Market Cap120.013B
Beta1.74
PE Ratio (TTM)131.05
EPS (TTM)0.52
Earnings DateOct 16, 2018 - Oct 22, 2018
Forward Dividend & Yield1.12 (1.64%)
Ex-Dividend Date2018-10-12
1y Target Est71.31
Trade prices are not sourced from all markets
  • A Look at Hologic Stock’s Recent Performance
    Market Realist8 hours ago

    A Look at Hologic Stock’s Recent Performance

    On September 17, Hologic (HOLX) ended the day at $39.53. The stock was down ~0.3% from its previous trading day’s closing price of $39.64. The stock has recuperated some of the losses it saw during the first half of fiscal 2018. It witnessed a declining trend after reporting its 52-week high of $45.09 on January 9, 2018.

  • ABT or PETQ: Which Is the Better Value Stock Right Now?
    Zacks13 hours ago

    ABT or PETQ: Which Is the Better Value Stock Right Now?

    ABT vs. PETQ: Which Stock Is the Better Value Option?

  • Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
    Zacks14 hours ago

    Here's Why You Should Add Abbott (ABT) to Your Portfolio Now

    Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.

  • Non-diabetics are using diabetes technology to track their blood sugar and improve their health
    MarketWatch14 hours ago

    Non-diabetics are using diabetes technology to track their blood sugar and improve their health

    About two months ago, grad student Azure Grant began wearing a glucose monitor every day. Diabetics have trouble regulating their glucose levels, and thus must track them closely. Here’s the catch: Grant doesn’t have diabetes.

  • A Look at Boston Scientific’s Valuation Multiples in September
    Market Realist2 days ago

    A Look at Boston Scientific’s Valuation Multiples in September

    On September 14, Boston Scientific (BSX) was trading at a forward PE (price-to-earnings) ratio of 24.4x, compared to the industry’s average PE ratio of 22.4x. Boston Scientific’s forward EV-to-EBITDA multiple is 19.1x, which is higher than the industry average of 16.7x. On September 14, Boston Scientific’s peers Abbott Laboratories (ABT), Edwards Lifesciences (EW), and Medtronic (MDT) had forward PE multiples of 21.7x, 28.4x, and 18.3x, respectively.

  • Boston Scientific Stock in the Week Ended September 14
    Market Realist2 days ago

    Boston Scientific Stock in the Week Ended September 14

    BSX stock is trading ~53.0% higher than its 52-week low of $24.54 reported on December 6, 2017. Over the last week, BSX stock has risen ~4.5%. BSX stock has risen ~11.6% over the last month. Year-to-date, BSX stock has reported stellar gains of ~52.0%.

  • Abbott Labs Declares Quarterly Dividend
    GuruFocus.com4 days ago

    Abbott Labs Declares Quarterly Dividend

    Abbott Laboratories (ABT) closed higher on the New York Stock Exchange on Sept. 13 after the board of directors declared a cash quarterly dividend of 28 cents. Warning! GuruFocus has detected 7 Warning Sign with ABT. Analysts expect 4% growth in the stock's market value, making Abbott Labs an appealing investment option.

  • Moody's4 days ago

    Abbott Ireland Financing DAC -- Moody's assigns Baa1 to Abbott Lab's proposed Euro notes offering

    Moody's Investors Service ("Moody's") today assigned Baa1 ratings to the senior unsecured notes to be offered by Abbott Ireland Financing DAC, a newly-formed financing subsidiary of Abbott Laboratories ("Abbott"). The outlook of Abbott Laboratories is positive. The rating outlook of Abbott Laboratories is positive.

  • Abbott Declares 379th Consecutive Quarterly Dividend
    PR Newswire5 days ago

    Abbott Declares 379th Consecutive Quarterly Dividend

    ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 28 cents per share. This marks the 379 th consecutive quarterly ...

  • Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
    PR Newswire5 days ago

    Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)

    ABBOTT PARK, Ill., Sept. 13, 2018 /PRNewswire/ -- For the sixth consecutive year, Abbott (ABT) has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI), one of the most prestigious global benchmarks for corporate sustainability and responsibility. As the industry leader in Health Care Equipment & Supplies, Abbott is one of the 60 companies recognized for leading their respective global industries.

  • JNJ Stock Up 7% in the Past Month: What Drove the Bulls?
    Market Realist6 days ago

    JNJ Stock Up 7% in the Past Month: What Drove the Bulls?

    On September 12, Johnson & Johnson (JNJ) stock closed at $139.36. That was a 0.61% rise from the previous day’s closing price of $138.51. Currently, JNJ stock is trading above its 50-day moving average of $133.29 and below its 200-day moving average of $127.99.

  • Reuters6 days ago

    India bans 328 combination drugs in setback for pharma companies

    The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Indian government had in 2016 banned about 350 such drugs, referred to as fixed-dose combinations (FDCs), but the industry mounted various legal challenges that prompted the Supreme Court to call for a review by an advisory board. The president of the Indian Drug Manufacturers' Association, Deepnath Roychowdhury, said the order would have an impact on a market worth an estimated 16 billion rupees ($222 million) a year for such drugs, which are produced by both small and large pharmaceutical companies.

  • How Thermo Fisher Fared in the Second Quarter
    Market Realist6 days ago

    How Thermo Fisher Fared in the Second Quarter

    Thermo Fisher Scientific (TMO) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during Q2 2018 and reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion during the quarter. The above chart compares the revenues since the first quarter of 2017.

  • 5 Growth Stocks to Buy for Reliable Income in Retirement
    InvestorPlace6 days ago

    5 Growth Stocks to Buy for Reliable Income in Retirement

    For this reason, some investors will resort to individual growth stocks. For example, dividend aristocrats, or stocks that have seen at least 25 consecutive years of dividend hikes, could bolster such a portfolio.

  • The Wall Street Journal8 days ago

    [$$] Brain Data Could Read Moods, Potentially Treat Depression

    Can mood be decoded from brain data? The work is part of a larger movement aimed at developing better, more personalized therapies for psychiatric conditions like depression, anxiety, post-traumatic stress disorder and obsessive compulsive disorder using deep brain stimulation, a procedure that requires surgery and is highly invasive. The approach is similar to treatments already in use for movement disorders like Parkinson’s disease and epilepsy.

  • Most Analysts Currently Call Boston Scientific a ‘Buy’
    Market Realist8 days ago

    Most Analysts Currently Call Boston Scientific a ‘Buy’

    Since January 2, Boston Scientific’s (BSX) share price has risen 41.4%. The company posted 6% YoY (year-over-year) organic revenue growth in the first half of 2018. The company is thus expected to witness revenue growth rates in the second half similar to those it witnessed in the first half.

  • Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake
    Zacks9 days ago

    Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake

    Abbott (ABT) to see a rise in customer adoption of its DRG therapy following the receipt of new national coverage from Aetna.

  • The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE
    Zacks9 days ago

    The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE

    The Zacks Analyst Blog Highlights: Abbott, Gilead, FedEx, Archer Daniels and CBRE

  • How Hologic’s Valuation Stacks Up with Peers
    Market Realist11 days ago

    How Hologic’s Valuation Stacks Up with Peers

    Hologic is a medical technology firm focused on developing solutions for women’s health. Year-to-date, Hologic stock is down ~9.6%. The event led to a ~4% decline in its stock price on August 13, when the announcement was made.

  • Zacks11 days ago

    Top Research Reports for Abbott, Gilead & FedEx

    Top Research Reports for Abbott, Gilead & FedEx

  • MS Global Franchise Fund Buys 1, Sells 4 in 2nd Quarter
    GuruFocus.com12 days ago

    MS Global Franchise Fund Buys 1, Sells 4 in 2nd Quarter

    Fund invests in Baxter International

  • What Alexion Pharmaceuticals’ Valuation Trend Indicates
    Market Realist13 days ago

    What Alexion Pharmaceuticals’ Valuation Trend Indicates

    In September 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given Alexion stock a “buy” or higher rating, and two analysts have given Alexion a “hold” rating. The mean rating for Alexion stock is $1.83 with a target price of $158.41, implying an upside potential of 32.9% over Alexion’s closing price of $119.20 on September 4.

  • Livongo Health expands under new offering with Abbott Labs
    TechCrunch13 days ago

    Livongo Health expands under new offering with Abbott Labs

    Livongo Health, a consumer digital health company is focused on the treatment of chronic diseases, is integrating its service with Abbott Labs' continuous glucose monitoring system. Livongo is about empowering people with chronic conditions live better and healthier lives, CEO Glen Tullman said on stage at Disrupt SF.  Livongo started with a connected blood glucose monitor that captures data and sends it to the cloud, where it can be processed and analyzed. From here, Livongo delivers real-time insights to customers as well as their physician and even family members.